A recent genome-wide analysis (GWAS) identified IL-12B as the gene susceptible to TAK.[4] Molecular therapy targeting IL-12 molecules and IL-12-associated receptors has also been highly focused on.[5] Meanwhile, IL-17 is an inflammatory cytokine produced downstream of IL-12 due to inflammation and is also known to be elevated in TAK.[6] We report a unique case in which secukinumab (SEC), an anti-IL-17 monoclonal antibody, was influential in the treatment of TAK complicated by generalized pustular psoriasis (GPP). Here, IL17A is linked to generalized pustular psoriasis.